Cargando…
Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes
A structure-based virtual screening of over 400,000 small molecules against the constitutive proteasome activity followed by in vitro assays led to the discovery of a family of proteasome inhibitors with a sulfonyl piperazine scaffold. Some members of this family of small non-peptidic inhibitors wer...
Autores principales: | Villoutreix, Bruno O., Khatib, Abdel-Majid, Cheng, Yan, Miteva, Maria A., Maréchal, Xavier, Vidal, Joëlle, Reboud-Ravaux, Michèle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354670/ https://www.ncbi.nlm.nih.gov/pubmed/28060729 http://dx.doi.org/10.18632/oncotarget.14428 |
Ejemplares similares
-
Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins
por: Nathan, James A., et al.
Publicado: (2013) -
The Molecular Mechanisms Governing the Assembly of the Immuno- and Thymoproteasomes in the Presence of Constitutive Proteasomes
por: Watanabe, Ayaka, et al.
Publicado: (2022) -
Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo
por: Tandon, Vasudha, et al.
Publicado: (2022) -
Mechanisms of noncovalent β subunit regulation of Na(V) channel gating
por: Zhu, Wandi, et al.
Publicado: (2017) -
(Immuno)proteasomes as therapeutic target in acute leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2017)